You are here

Obesity Drug Saxenda (Liraglutide) Launched in U.S.

First GLP-1 receptor agonist approved for weight management

Saxenda (liraglutide 3 mg, Novo Nordisk), the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in the U.S. –– is now available for clinical use in this country. The drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (body mass index [BMI] greater than or equal to 30 kg/m2) or who are overweight (BMI greater than or equal to 27 kg/m2) in the presence of at least one weight-related comorbid condition.

Liraglutide was evaluated in the phase III SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence in Nondiabetic and Diabetic People) clinical trial program, which involved more than 5,000 study participants who had obesity or who were overweight, with weight-related comorbidities. The trial data showed that liraglutide, in combination with a reduced-calorie diet and increased physical activity, resulted in greater weight loss compared with a reduced-calorie diet and physical activity alone.

Recognized as a disease by the American Medical Association and other medical societies, obesity has grown in prevalence in the U.S. and around the world. Affecting approximately 35% of the U.S. adult population in 2011–2012, obesity is associated with serious comorbidities, including type-2 diabetes, heart disease, and certain types of cancer.

Liraglutide is a once-daily GLP-1 analogue with 97% similarity to naturally occurring human GLP-1, a hormone that is released in response to food intake. Like human GLP-1, liraglutide regulates the appetite and lowers body weight through decreased food intake. As with other GLP-1 receptor agonists, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of blood glucose.

The labeling for Saxenda includes a boxed warning regarding the risk for thyroid C-cell tumors. The most common adverse events related to treatment include nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase.

Sources: Novo Nordisk; April 22, 2015; and Saxenda Prescribing Information; January 2015.

 

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial